Fluidigm (NASDAQ:FLDM) will issue its quarterly earnings data after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Fluidigm has set its Q3 2019 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.
Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings data on Thursday, August 1st. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.08). Fluidigm had a negative return on equity of 31.45% and a negative net margin of 57.48%. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $30.16 million. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts expect Fluidigm to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ FLDM opened at $4.63 on Tuesday. Fluidigm has a 52-week low of $4.03 and a 52-week high of $14.90. The company has a quick ratio of 2.48, a current ratio of 2.86 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $4.87 and a 200-day moving average of $9.33.
FLDM has been the subject of a number of research analyst reports. UBS Group raised shares of Fluidigm from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $14.00 to $7.00 in a report on Friday, October 18th. BidaskClub raised shares of Fluidigm from a “strong sell” rating to a “sell” rating in a report on Saturday, October 19th. Finally, Zacks Investment Research raised shares of Fluidigm from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Fluidigm has an average rating of “Buy” and a consensus price target of $10.81.
In other Fluidigm news, Director Samuel D. Colella purchased 9,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was acquired at an average cost of $7.00 per share, with a total value of $63,000.00. Following the completion of the purchase, the director now directly owns 115,481 shares of the company’s stock, valued at approximately $808,367. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Levin Easterly Partners Llc sold 151,011 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $7.01, for a total transaction of $1,058,587.11. The disclosure for this sale can be found here. Over the last three months, insiders acquired 15,000 shares of company stock valued at $95,460 and sold 870,619 shares valued at $5,151,216. Insiders own 2.00% of the company’s stock.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Recommended Story: Risk Tolerance
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.